The new Center for Personalized Medicine (CPM) at Roswell Park Cancer Institute (RPCI) shares below why they purchased four Ion Proton™ sequencers and two Ion Personal Genome Machine™ (PGM™) sequencers.
Founded in 1898, Roswell Park Cancer Institute was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and is a member of the prestigious National Comprehensive Cancer Network.
Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine:
“A key part of our mission at the Center involves research into new therapies, new diagnostic tools and better ways of predicting patient outcomes.” “The sequencers will be central to this work, quickly generating vast amounts of genomic data that will help us to understand the mechanisms of how cancer develops and spreads.”
Life Technologies Chief Operating Officer Mark Stevenson:
“The combination of the Ion Proton™ sequencer and the Ion PGM™ sequencer will give the researchers from Roswell Park Cancer Institute a simple workflow from discovery to validation.” “Over 1,000 organizations have adopted Ion Torrent technology in the past two years, giving our company more than 60 percent of the desktop sequencer market and reflecting the huge demand for the speed, simplicity and affordability of Ion Torrent technology.”